Triglycerides: the lipid that moves the most
Triglycerides respond to the last meal, the last drink and the last few weeks of weight change. That makes them noisy as a snapshot and very useful as a trend.
Triglycerides are the main form of fat the body stores and burns. In the blood they travel inside lipoprotein particles, mostly VLDL made by the liver and chylomicrons made by the gut after a meal. A triglyceride result is reported in mg/dL in the US and mmol/L elsewhere (divide mg/dL by 88.5 to convert). It is part of every standard lipid panel, and it is also used to calculate LDL in many labs.
The guideline numbers
| Triglycerides | Category | Source |
|---|---|---|
| Under 150 mg/dL (fasting) | Normal | NCEP ATP III |
| 150 to 199 mg/dL | Borderline high | NCEP ATP III |
| 200 to 499 mg/dL | High | NCEP ATP III |
| 500 mg/dL or more | Very high (severe) | NCEP ATP III; ACC/AHA 2018 |
| 175 mg/dL or more, persistently | Risk-enhancing factor | ACC/AHA 2018 |
| 175 mg/dL or more (non-fasting) | Flag as abnormal on a non-fasting report | EAS/EFLM 2016 |
| Over 880 mg/dL (10 mmol/L) | Refer: pancreatitis risk | EAS/EFLM 2016 |
Online "optimal" figures of under 100 or even under 70 mg/dL come from the observation that risk keeps falling at lower levels. That is consistent with the data, but no guideline sets those numbers as targets.
What raises and lowers them
- Raises: a recent meal, alcohol, refined carbohydrate and sugar, excess weight and insulin resistance, poorly controlled diabetes, an underactive thyroid, kidney disease, pregnancy, some drugs (including steroids, some HIV drugs and retinoids), and inherited conditions.
- Lowers: weight loss, cutting alcohol and sugar, exercise, omega-3 at prescription doses, fibrates and statins, and better glucose control.
What it predicts
In the Copenhagen City Heart Study (JAMA, 2007), 7,587 women and 6,394 men had non-fasting triglycerides measured and were followed for a mean of 26 years. Risk rose steadily with level. In women, those at 5 mmol/L (442 mg/dL) or more had a multifactorially adjusted hazard ratio for heart attack of 5.4 compared with under 1 mmol/L (89 mg/dL). The finding that non-fasting levels predict as well as fasting ones fed into the 2016 EAS/EFLM consensus that fasting is not routinely needed.
Genetics adds an important twist. A 2019 Mendelian randomisation study of 654,783 people found that gene variants lowering triglycerides reduced heart disease risk by the same amount as variants lowering LDL, per unit of ApoB lowered. Once ApoB was accounted for, triglycerides added nothing. In other words, triglycerides matter mainly through the number of particles carrying them; see the ApoB page.
On GLP-1 drugs and weight loss
Triglycerides fall more than any other lipid on these drugs:
| Trial | Drug and dose | Length | Triglycerides vs placebo |
|---|---|---|---|
| STEP 1 (n=1,961) | Semaglutide 2.4 mg | 68 weeks | -21.9% vs -7.3% |
| SURMOUNT-1 (n=2,539, four arms) | Tirzepatide 15 mg | 72 weeks | -29.1% vs -5.6% |
| SELECT (n=17,604) | Semaglutide 2.4 mg | 104 weeks | -18.3% vs -3.2% |
These are secondary measures, not controlled for multiple testing, so read them as direction and size. The GLP-1 blood work page has the full lipid table.
How to test
- Non-fasting is acceptable for routine screening, per the EAS/EFLM. A normal meal raises triglycerides by up to about 26 mg/dL on average.
- Fast 9 to 12 hours if a previous non-fasting result was over 440 mg/dL, or if you want results comparable with old fasting ones. Pick one approach and stick to it.
- No alcohol for 24 to 48 hours beforehand.
- Expect variation. Triglycerides vary more from day to day in the same person than any other lipid. Look at the trend across several draws.
Tracking it in Peptide AI
In Peptide AI, triglycerides sits in the metabolic panel. The app reads it from a lab PDF or manual entry, scores the panel from 0 to 100 alongside an overall grade, flags values that warrant prompt physician consultation, and plots each result against your dose timeline. Meals logged in nutrition tracking show what you ate the day before the draw. Log the draw date, whether you fasted, and anything unusual in the days before, such as illness, a hard session or a dose step, so the next result is compared like with like. Bloodwork tracking shows the series next to the dose log, weight and side effects, and the panels page lists every marker the app groups. More markers are in the bloodwork guides.
Questions people ask
What is a normal triglyceride level?
Under 150 mg/dL fasting by NCEP ATP III. 150 to 199 is borderline high, 200 to 499 is high and 500 or more is very high. For non-fasting samples the EAS/EFLM flags 175 mg/dL or more.
Do I need to fast for a triglyceride test?
Not usually. The 2016 EAS/EFLM consensus recommends non-fasting lipid profiles for routine use and fasting when a non-fasting result is over 440 mg/dL.
How much do GLP-1 drugs lower triglycerides?
In STEP 1, semaglutide 2.4 mg lowered triglycerides 21.9% against 7.3% on placebo. In SURMOUNT-1, tirzepatide 15 mg lowered them 29.1% against 5.6%.
At what level do triglycerides cause pancreatitis?
The EAS/EFLM consensus calls for separate referral above 880 mg/dL (10 mmol/L) because of pancreatitis risk. The ACC/AHA treats 500 mg/dL or more as severe.
Why do my triglycerides change so much between tests?
They respond to the previous meal, alcohol, recent weight change and exercise, and they have the highest day-to-day variation of the standard lipids.
Sources
- Third Report of the National Cholesterol Education Program (NCEP) Expert Panel (Adult Treatment Panel III), final report, Circulation, 2002
- 2018 AHA/ACC multisociety guideline on the management of blood cholesterol, Grundy et al., Circulation, 2019
- Fasting is not routinely required for determination of a lipid profile: joint consensus statement from the EAS and EFLM, Nordestgaard et al., European Heart Journal, 2016
- Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women, Nordestgaard et al., JAMA, 2007
- Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease, Ference et al., JAMA, 2019
- Wegovy prescribing information, Novo Nordisk
- Zepbound prescribing information, Eli Lilly
- Once-weekly semaglutide in adults with overweight or obesity (STEP 1), Wilding et al., New England Journal of Medicine, 2021
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1), Jastreboff et al., New England Journal of Medicine, 2022
- Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT), Lincoff et al., New England Journal of Medicine, 2023
